123 related articles for article (PubMed ID: 6460555)
1. Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells.
Marsh JC
Cancer Treat Rep; 1982 Mar; 66(3):499-504. PubMed ID: 6460555
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin antagonizes the effects of trimetrexate on mouse hemopoietic progenitors.
Lerza R; Mencoboni M; Bogliolo G; Flego G; Gasparini L; Pannacciulli I
Anticancer Res; 1991; 11(2):613-6. PubMed ID: 1829599
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of trimetrexate on hemopoietic progenitor cells in normal mice.
Bogliolo GV; Lerza RA; Mencoboni MP; Saviane AG; Pannacciulli IM
Anticancer Res; 1988; 8(2):229-31. PubMed ID: 2966606
[TBL] [Abstract][Full Text] [Related]
4. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA synthesis in normal and malignant human cells by triazinate (Baker's antifol) and methotrexate.
Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
Cancer Res; 1976 Oct; 36(10):3659-64. PubMed ID: 953990
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the sensitivities of human, canine, and murine hematopoietic precursor cells to adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Marsh JC
Cancer Res; 1979 Feb; 39(2 Pt 1):360-4. PubMed ID: 761207
[TBL] [Abstract][Full Text] [Related]
7. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action.
Rosenthal GJ; Weigand GW; Germolec DR; Blank JA; Luster MI
J Immunol; 1988 Jul; 141(2):410-6. PubMed ID: 2968399
[TBL] [Abstract][Full Text] [Related]
8. Correlation of hematologic toxicity of antineoplastic agents with their effects on bone marrow stem cells: interspecies studies using an in vivo assay.
Marsh JC
Exp Hematol; 1985; 13 Suppl 16():16-22. PubMed ID: 3987835
[TBL] [Abstract][Full Text] [Related]
9. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
10. Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
Sobrero AF; Bertino JR
Int J Cell Cloning; 1986 Jan; 4(1):51-62. PubMed ID: 2936838
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effects of nine folate analogs on early and late murine hematopoietic progenitor cells in vitro.
Strømhaug A; Warren DJ
Cancer Chemother Pharmacol; 2000; 45(6):450-6. PubMed ID: 10854131
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.
Belur LR; James RI; May C; Diers MD; Swanson D; Gunther R; McIvor RS
J Pharmacol Exp Ther; 2005 Aug; 314(2):668-74. PubMed ID: 15857949
[TBL] [Abstract][Full Text] [Related]
13. Incidence and characteristics of colony-forming units fibroblasts (CFU-F) in the bone marrow of weanling mice treated with cytosine arabinoside and phenylhydrazine: correlation with CFU-S, progenitors of diffusion-chamber colonies (CFU-D), and CFU-C.
Ben-Ishay Z; Borenstein A; Sharon S; Prindull G
Int J Cell Cloning; 1983 Oct; 1(5):343-59. PubMed ID: 6672102
[TBL] [Abstract][Full Text] [Related]
14. The sensitivities of human and murine hemopoietic cells exposed to cytotoxic drugs in an in vivo culture system.
Gordon MY; Blackett N
Cancer Res; 1976 Aug; 36(8):2822-6. PubMed ID: 1277192
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of cytosine arabinoside and thiopurines.
Valeriote F; Vietti T; Edelstein M
Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
[TBL] [Abstract][Full Text] [Related]
16. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate.
James RI; May C; Vagt MD; Studebaker R; McIvor RS
Exp Hematol; 1997 Nov; 25(12):1286-95. PubMed ID: 9357973
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Marsh JC; Brown BJ; Nierenburg MM
Cancer Res; 1983 Jun; 43(6):2962-6. PubMed ID: 6573955
[TBL] [Abstract][Full Text] [Related]
19. Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Rodenhuis S; McGuire JJ; Sawicki WL; Bertino JR
Leukemia; 1987 Feb; 1(2):116-20. PubMed ID: 2959824
[TBL] [Abstract][Full Text] [Related]
20. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
